# Dosing Flexibility Study in Patients With Rheumatoid Arthritis

> **NCT00580840** · PHASE4 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 333 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab pegol
- **DRUG:** Certolizumab pegol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00580840
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580840, "Dosing Flexibility Study in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00580840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*